GlassScriptPhysician profile
Brielle Byrd
NPI 1629857164
$945.05
in general payments reported to CMS, 2019-2025
20 companies · $539 in 2025
The $539 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $60.18 · 2024: $345 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $127.23 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $124.68 | 2025 | |
| Pfizer INC. | $110.20 | 2024-2025 | |
| Corium, LLC | $86.34 | 2023-2025 | Azstarys |
| Verity Pharmaceuticals INC. | $60.42 | 2025 | Tlando |
| Exact Sciences Corporation | $60.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $58.18 | 2025 | Ozempic, Wegovy |
| Tolmar, INC. | $53.31 | 2023-2024 | |
| Tris Pharma INC | $42.22 | 2024-2025 | Dyanavel Xr |
| Lilly USA, LLC | $34.02 | 2024-2025 | Mounjaro |
| Inspire Medical Systems, INC. | $27.23 | 2025 | Inspire |
| Acella Pharmaceuticals, LLC | $25.83 | 2024 | NP Thyroid 60 |
| Supernus Pharmaceuticals, INC. | $24.58 | 2025 | Qelbree |
| Medtronic, INC. | $24.14 | 2025 | Inceptiv |
| Neos Therapeutics, LP | $18.36 | 2024 | Adzenys Xr-Odt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $16.88 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $16.30 | 2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $14.86 | 2025 | Breztri |
| Mayne Pharma Commercial LLC | $12.41 | 2025 | |
| Evofem Biosciences, INC. | $7.44 | 2025 | Phexxi, Solosec, Phexx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brielle Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.